JP2018531914A

JP2018531914A - ＣＤ１５５／ＴＩＧＩＴ経路およびＴＧＦ−βのアンタゴニストを介してがんを処置するための組成物および方法

ＣＤ１５５／ＴＩＧＩＴ経路およびＴＧＦ−βのアンタゴニストを介してがんを処置するための組成物および方法 Download PDF

Info

Publication number: JP2018531914A
Authority: JP; Japan
Prior art keywords: tgf; antagonist; cancer; tigit; patient
Prior art date: 2015-09-14
Legal status : Withdrawn

Application number

JP2018513505A

Other languages

English (en)

Japanese (ja)

Other versions

JP2018531914A5 (enExample

Inventor

ヘレンサブゼバリ，

サイモンメテノウ，

Original Assignee

コンパスセラピューティクスリミテッドライアビリティカンパニー

Priority date

2015-09-14

Filing date

2016-09-14

Publication date

2018-11-01

2016-09-14 Application filed by コンパスセラピューティクスリミテッドライアビリティカンパニー, コンパスセラピューティクスリミテッドライアビリティカンパニー filed Critical コンパスセラピューティクスリミテッドライアビリティカンパニー

2018-11-01 Publication of JP2018531914A publication Critical patent/JP2018531914A/ja

2019-10-31 Publication of JP2018531914A5 publication Critical patent/JP2018531914A5/ja

Status Withdrawn legal-status Critical Current

Links

239000005557 antagonist Substances 0.000 title claims abstract description 360
102100029740 Poliovirus receptor Human genes 0.000 title claims abstract description 271
108010048507 poliovirus receptor Proteins 0.000 title claims abstract description 266
102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 title claims abstract description 256
101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 title claims abstract description 254
206010028980 Neoplasm Diseases 0.000 title claims abstract description 239
201000011510 cancer Diseases 0.000 title claims abstract description 202
238000000034 method Methods 0.000 title claims description 236
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title description 181
102000004887 Transforming Growth Factor beta Human genes 0.000 title description 176
108090001012 Transforming Growth Factor beta Proteins 0.000 title description 176
239000000203 mixture Substances 0.000 title description 55
230000037361 pathway Effects 0.000 title description 37
102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims abstract description 213
101800002279 Transforming growth factor beta-1 Proteins 0.000 claims abstract description 213
210000004027 cell Anatomy 0.000 claims abstract description 143
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 52
238000004519 manufacturing process Methods 0.000 claims abstract description 19
108090000765 processed proteins & peptides Proteins 0.000 claims description 146
102000004196 processed proteins & peptides Human genes 0.000 claims description 117
229920001184 polypeptide Polymers 0.000 claims description 105
230000027455 binding Effects 0.000 claims description 103
108091005735 TGF-beta receptors Proteins 0.000 claims description 98
102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 98
239000012634 fragment Substances 0.000 claims description 72
239000000427 antigen Substances 0.000 claims description 66
108091007433 antigens Proteins 0.000 claims description 65
102000036639 antigens Human genes 0.000 claims description 65
229920001223 polyethylene glycol Polymers 0.000 claims description 65
239000002202 Polyethylene glycol Substances 0.000 claims description 57
150000001413 amino acids Chemical group 0.000 claims description 57
230000028993 immune response Effects 0.000 claims description 57
210000002966 serum Anatomy 0.000 claims description 47
238000011282 treatment Methods 0.000 claims description 41
230000002708 enhancing effect Effects 0.000 claims description 35
150000007523 nucleic acids Chemical class 0.000 claims description 33
230000005867 T cell response Effects 0.000 claims description 32
102000039446 nucleic acids Human genes 0.000 claims description 31
108020004707 nucleic acids Proteins 0.000 claims description 31
108020001507 fusion proteins Proteins 0.000 claims description 20
102000037865 fusion proteins Human genes 0.000 claims description 20
102000005962 receptors Human genes 0.000 claims description 19
108020003175 receptors Proteins 0.000 claims description 19
150000003384 small molecules Chemical class 0.000 claims description 16
108010002350 Interleukin-2 Proteins 0.000 claims description 12
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
230000035755 proliferation Effects 0.000 claims description 7
102000009027 Albumins Human genes 0.000 claims description 5
108010088751 Albumins Proteins 0.000 claims description 5
230000037455 tumor specific immune response Effects 0.000 claims description 4
230000000694 effects Effects 0.000 abstract description 19
206010006187 Breast cancer Diseases 0.000 abstract description 15
208000026310 Breast neoplasm Diseases 0.000 abstract description 15
230000001965 increasing effect Effects 0.000 abstract description 9
101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 abstract description 7
102100037850 Interferon gamma Human genes 0.000 abstract description 7
108010074328 Interferon-gamma Proteins 0.000 abstract description 7
101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract description 4
102000016289 Cell Adhesion Molecules Human genes 0.000 abstract description 2
102000027596 immune receptors Human genes 0.000 abstract 1
108091008915 immune receptors Proteins 0.000 abstract 1
239000002876 beta blocker Substances 0.000 description 109
230000014509 gene expression Effects 0.000 description 102
108090000623 proteins and genes Proteins 0.000 description 90
230000008859 change Effects 0.000 description 86
230000035772 mutation Effects 0.000 description 70
230000003321 amplification Effects 0.000 description 67
238000003199 nucleic acid amplification method Methods 0.000 description 67
102000004169 proteins and genes Human genes 0.000 description 58
235000001014 amino acid Nutrition 0.000 description 53
235000018102 proteins Nutrition 0.000 description 51
229940024606 amino acid Drugs 0.000 description 48
125000003275 alpha amino acid group Chemical group 0.000 description 47
238000012217 deletion Methods 0.000 description 33
230000037430 deletion Effects 0.000 description 33
108060003951 Immunoglobulin Proteins 0.000 description 29
102000018358 immunoglobulin Human genes 0.000 description 29
239000000523 sample Substances 0.000 description 27
230000011664 signaling Effects 0.000 description 27
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 26
125000000539 amino acid group Chemical group 0.000 description 25
210000001519 tissue Anatomy 0.000 description 25
108020004414 DNA Proteins 0.000 description 24
108020004999 messenger RNA Proteins 0.000 description 24
210000004881 tumor cell Anatomy 0.000 description 23
239000013598 vector Substances 0.000 description 23
238000003556 assay Methods 0.000 description 22
230000006870 function Effects 0.000 description 22
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 21
230000003993 interaction Effects 0.000 description 21
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 20
239000008194 pharmaceutical composition Substances 0.000 description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
206010009944 Colon cancer Diseases 0.000 description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
239000002773 nucleotide Substances 0.000 description 17
125000003729 nucleotide group Chemical group 0.000 description 17
102100040678 Programmed cell death protein 1 Human genes 0.000 description 16
238000009472 formulation Methods 0.000 description 16
208000001333 Colorectal Neoplasms Diseases 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 15
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 15
230000004927 fusion Effects 0.000 description 14
201000009030 Carcinoma Diseases 0.000 description 13
206010033128 Ovarian cancer Diseases 0.000 description 13
206010061535 Ovarian neoplasm Diseases 0.000 description 13
102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 13
230000000903 blocking effect Effects 0.000 description 13
239000003112 inhibitor Substances 0.000 description 13
150000001875 compounds Chemical class 0.000 description 12
238000006467 substitution reaction Methods 0.000 description 12
108091028043 Nucleic acid sequence Proteins 0.000 description 11
102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 11
101800000304 Transforming growth factor beta-2 Proteins 0.000 description 11
108090000097 Transforming growth factor beta-3 Proteins 0.000 description 11
102000056172 Transforming growth factor beta-3 Human genes 0.000 description 11
239000002671 adjuvant Substances 0.000 description 11
239000003153 chemical reaction reagent Substances 0.000 description 11
230000021615 conjugation Effects 0.000 description 11
230000002401 inhibitory effect Effects 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 11
239000003446 ligand Substances 0.000 description 11
230000004044 response Effects 0.000 description 11
238000012360 testing method Methods 0.000 description 11
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 11
241000894006 Bacteria Species 0.000 description 10
102100038077 CD226 antigen Human genes 0.000 description 10
BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 10
101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 10
101710089372 Programmed cell death protein 1 Proteins 0.000 description 10
102000007562 Serum Albumin Human genes 0.000 description 10
108010071390 Serum Albumin Proteins 0.000 description 10
238000004422 calculation algorithm Methods 0.000 description 10
238000006471 dimerization reaction Methods 0.000 description 10
210000002865 immune cell Anatomy 0.000 description 10
201000001441 melanoma Diseases 0.000 description 10
239000000126 substance Substances 0.000 description 10
102000008100 Human Serum Albumin Human genes 0.000 description 9
108091006905 Human Serum Albumin Proteins 0.000 description 9
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
239000000463 material Substances 0.000 description 9
208000002154 non-small cell lung carcinoma Diseases 0.000 description 9
230000009261 transgenic effect Effects 0.000 description 9
108010074708 B7-H1 Antigen Proteins 0.000 description 8
102000053602 DNA Human genes 0.000 description 8
241000238631 Hexapoda Species 0.000 description 8
-1 IL-12p70 Proteins 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
206010060862 Prostate cancer Diseases 0.000 description 8
208000006265 Renal cell carcinoma Diseases 0.000 description 8
206010039491 Sarcoma Diseases 0.000 description 8
210000004443 dendritic cell Anatomy 0.000 description 8
201000010099 disease Diseases 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
210000000822 natural killer cell Anatomy 0.000 description 8
210000000056 organ Anatomy 0.000 description 8
230000006320 pegylation Effects 0.000 description 8
239000007790 solid phase Substances 0.000 description 8
241000894007 species Species 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
229940121779 CD155 antagonist Drugs 0.000 description 7
206010008342 Cervix carcinoma Diseases 0.000 description 7
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 7
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 7
206010058467 Lung neoplasm malignant Diseases 0.000 description 7
241000124008 Mammalia Species 0.000 description 7
208000000236 Prostatic Neoplasms Diseases 0.000 description 7
208000005718 Stomach Neoplasms Diseases 0.000 description 7
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 7
239000002585 base Substances 0.000 description 7
201000010881 cervical cancer Diseases 0.000 description 7
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
230000016396 cytokine production Effects 0.000 description 7
206010017758 gastric cancer Diseases 0.000 description 7
208000005017 glioblastoma Diseases 0.000 description 7
210000004408 hybridoma Anatomy 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
102000040430 polynucleotide Human genes 0.000 description 7
108091033319 polynucleotide Proteins 0.000 description 7
238000003127 radioimmunoassay Methods 0.000 description 7
201000011549 stomach cancer Diseases 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
238000002965 ELISA Methods 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 6
101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 6
101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 6
108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
102000002356 Nectin Human genes 0.000 description 6
108060005251 Nectin Proteins 0.000 description 6
206010030155 Oesophageal carcinoma Diseases 0.000 description 6
206010035226 Plasma cell myeloma Diseases 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000006044 T cell activation Effects 0.000 description 6
230000006052 T cell proliferation Effects 0.000 description 6
125000003277 amino group Chemical group 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 6
238000002648 combination therapy Methods 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
239000000539 dimer Substances 0.000 description 6
210000004602 germ cell Anatomy 0.000 description 6
230000036737 immune function Effects 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
230000002163 immunogen Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
239000002157 polynucleotide Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000013456 study Methods 0.000 description 6
238000013268 sustained release Methods 0.000 description 6
239000012730 sustained-release form Substances 0.000 description 6
206010005003 Bladder cancer Diseases 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 5
108090000695 Cytokines Proteins 0.000 description 5
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
208000000461 Esophageal Neoplasms Diseases 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
239000004471 Glycine Substances 0.000 description 5
101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
108700011259 MicroRNAs Proteins 0.000 description 5
206010061902 Pancreatic neoplasm Diseases 0.000 description 5
108091027967 Small hairpin RNA Proteins 0.000 description 5
208000002495 Uterine Neoplasms Diseases 0.000 description 5
239000000074 antisense oligonucleotide Substances 0.000 description 5
238000012230 antisense oligonucleotides Methods 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
208000006990 cholangiocarcinoma Diseases 0.000 description 5
238000004132 cross linking Methods 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000012636 effector Substances 0.000 description 5
201000004101 esophageal cancer Diseases 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
230000012010 growth Effects 0.000 description 5
230000003463 hyperproliferative effect Effects 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
201000005296 lung carcinoma Diseases 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
238000013507 mapping Methods 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
239000002679 microRNA Substances 0.000 description 5
201000002528 pancreatic cancer Diseases 0.000 description 5
208000008443 pancreatic carcinoma Diseases 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
230000009919 sequestration Effects 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
239000004055 small Interfering RNA Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000000600 sorbitol Substances 0.000 description 5
125000006850 spacer group Chemical group 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
206010046766 uterine cancer Diseases 0.000 description 5
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
108091023037 Aptamer Proteins 0.000 description 4
239000004475 Arginine Substances 0.000 description 4
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
208000030808 Clear cell renal carcinoma Diseases 0.000 description 4
239000004971 Cross linker Substances 0.000 description 4
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 4
101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 4
108010029485 Protein Isoforms Proteins 0.000 description 4
102000001708 Protein Isoforms Human genes 0.000 description 4
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
102000004338 Transferrin Human genes 0.000 description 4
108090000901 Transferrin Proteins 0.000 description 4
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000013543 active substance Substances 0.000 description 4
208000009956 adenocarcinoma Diseases 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
210000000481 breast Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
206010073251 clear cell renal cell carcinoma Diseases 0.000 description 4
238000012875 competitive assay Methods 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
239000003184 complementary RNA Substances 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
230000006378 damage Effects 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
201000010536 head and neck cancer Diseases 0.000 description 4
208000014829 head and neck neoplasm Diseases 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
238000001114 immunoprecipitation Methods 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
201000007270 liver cancer Diseases 0.000 description 4
208000014018 liver neoplasm Diseases 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
201000005249 lung adenocarcinoma Diseases 0.000 description 4
201000000050 myeloid neoplasm Diseases 0.000 description 4
230000003472 neutralizing effect Effects 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
108091092562 ribozyme Proteins 0.000 description 4
210000002536 stromal cell Anatomy 0.000 description 4
239000003826 tablet Substances 0.000 description 4
125000003396 thiol group Chemical group [H]S* 0.000 description 4
239000012581 transferrin Substances 0.000 description 4
201000005112 urinary bladder cancer Diseases 0.000 description 4
108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
108020005544 Antisense RNA Proteins 0.000 description 3
206010003445 Ascites Diseases 0.000 description 3
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
229940045513 CTLA4 antagonist Drugs 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000283086 Equidae Species 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
206010027406 Mesothelioma Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 3
101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
101710204410 Scaffold protein Proteins 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
241000282887 Suidae Species 0.000 description 3
102100035268 T-cell surface protein tactile Human genes 0.000 description 3
208000024313 Testicular Neoplasms Diseases 0.000 description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
239000004473 Threonine Substances 0.000 description 3
102000040945 Transcription factor Human genes 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
230000036039 immunity Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
238000002513 implantation Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000002372 labelling Methods 0.000 description 3
208000030173 low grade glioma Diseases 0.000 description 3
201000005243 lung squamous cell carcinoma Diseases 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000003550 marker Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
206010061289 metastatic neoplasm Diseases 0.000 description 3
230000001613 neoplastic effect Effects 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
201000010279 papillary renal cell carcinoma Diseases 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
238000002823 phage display Methods 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000006722 reduction reaction Methods 0.000 description 3
239000013074 reference sample Substances 0.000 description 3
210000003289 regulatory T cell Anatomy 0.000 description 3
238000012552 review Methods 0.000 description 3
230000007017 scission Effects 0.000 description 3
208000000587 small cell lung carcinoma Diseases 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
238000010186 staining Methods 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
201000003120 testicular cancer Diseases 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
206010004146 Basal cell carcinoma Diseases 0.000 description 2
206010004593 Bile duct cancer Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102000008203 CTLA-4 Antigen Human genes 0.000 description 2
108010021064 CTLA-4 Antigen Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000283707 Capra Species 0.000 description 2
208000006332 Choriocarcinoma Diseases 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
238000011238 DNA vaccination Methods 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
102000016359 Fibronectins Human genes 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000699694 Gerbillinae Species 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
101000908688 Homo sapiens Dynein light chain Tctex-type 1 Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
108010067902 Peptide Library Proteins 0.000 description 2
102100024952 Protein CBFA2T1 Human genes 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
201000000582 Retinoblastoma Diseases 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
206010041067 Small cell lung cancer Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
108091027076 Spiegelmer Proteins 0.000 description 2
102100033456 TGF-beta receptor type-1 Human genes 0.000 description 2
101710084191 TGF-beta receptor type-1 Proteins 0.000 description 2
206010057644 Testis cancer Diseases 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
101710162629 Trypsin inhibitor Proteins 0.000 description 2
229940122618 Trypsin inhibitor Drugs 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
239000000556 agonist Substances 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
229940124650 anti-cancer therapies Drugs 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
238000011319 anticancer therapy Methods 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
208000026900 bile duct neoplasm Diseases 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
239000011616 biotin Substances 0.000 description 2
PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
201000008274 breast adenocarcinoma Diseases 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Chemical group 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000021164 cell adhesion Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000012292 cell migration Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
201000010989 colorectal carcinoma Diseases 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
239000003797 essential amino acid Substances 0.000 description 2
235000020776 essential amino acid Nutrition 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000003325 follicular Effects 0.000 description 2
238000002825 functional assay Methods 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
230000000762 glandular Effects 0.000 description 2
229960002989 glutamic acid Drugs 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
102000049823 human TIGIT Human genes 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
229960003160 hyaluronic acid Drugs 0.000 description 2
210000004754 hybrid cell Anatomy 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
238000011532 immunohistochemical staining Methods 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000001788 irregular Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000003071 memory t lymphocyte Anatomy 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
238000013508 migration Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229960003301 nivolumab Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
229960002621 pembrolizumab Drugs 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229950008882 polysorbate Drugs 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000007015 preclinical effect Effects 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
238000003860 storage Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
108091007466 transmembrane glycoproteins Proteins 0.000 description 2
102000035160 transmembrane proteins Human genes 0.000 description 2
108091005703 transmembrane proteins Proteins 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
239000004474 valine Substances 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
FUOJEDZPVVDXHI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-azido-2-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC=C(N=[N+]=[N-])C=C1C(=O)ON1C(=O)CCC1=O FUOJEDZPVVDXHI-UHFFFAOYSA-N 0.000 description 1
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
FQWZLZJRZNURGX-BYPYZUCNSA-N (2s)-2-(2-diazohydrazinyl)-4-methylsulfanylbutanoic acid Chemical group CSCC[C@@H](C(O)=O)NN=[N+]=[N-] FQWZLZJRZNURGX-BYPYZUCNSA-N 0.000 description 1
XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
WXXSHAKLDCERGU-UHFFFAOYSA-N 1-[4-(2,5-dioxopyrrol-1-yl)butyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCCCN1C(=O)C=CC1=O WXXSHAKLDCERGU-UHFFFAOYSA-N 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
CBYYPIYKJZCKGK-UHFFFAOYSA-N 2-(4-azidophenyl)-2-oxoacetaldehyde;hydrate Chemical compound O.[N-]=[N+]=NC1=CC=C(C(=O)C=O)C=C1 CBYYPIYKJZCKGK-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
101100256985 Arabidopsis thaliana SIS3 gene Proteins 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
241000282828 Camelus bactrianus Species 0.000 description 1
241000282836 Camelus dromedarius Species 0.000 description 1
101000841393 Candida albicans Probable NADPH dehydrogenase Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
201000000274 Carcinosarcoma Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
108010039939 Cell Wall Skeleton Proteins 0.000 description 1
206010007953 Central nervous system lymphoma Diseases 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
208000002699 Digestive System Neoplasms Diseases 0.000 description 1
235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
102100024749 Dynein light chain Tctex-type 1 Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102100037241 Endoglin Human genes 0.000 description 1
108010036395 Endoglin Proteins 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
239000001116 FEMA 4028 Substances 0.000 description 1
108010008177 Fd immunoglobulins Proteins 0.000 description 1
102000002090 Fibronectin type III Human genes 0.000 description 1
108050009401 Fibronectin type III Proteins 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
101710088570 Flagellar hook-associated protein 1 Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102100039556 Galectin-4 Human genes 0.000 description 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
102000001398 Granzyme Human genes 0.000 description 1
108060005986 Granzyme Proteins 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000866618 Homo sapiens 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Proteins 0.000 description 1
101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 description 1
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
101100510618 Homo sapiens LAG3 gene Proteins 0.000 description 1
101000616556 Homo sapiens SH3 domain-containing protein 19 Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000037982 Immune checkpoint proteins Human genes 0.000 description 1
108091008036 Immune checkpoint proteins Proteins 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
101150030213 Lag3 gene Proteins 0.000 description 1
241000282838 Lama Species 0.000 description 1
206010023825 Laryngeal cancer Diseases 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
102000019298 Lipocalin Human genes 0.000 description 1
108050006654 Lipocalin Proteins 0.000 description 1
102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000282553 Macaca Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
208000007054 Medullary Carcinoma Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
102100030590 Mothers against decapentaplegic homolog 6 Human genes 0.000 description 1
101710143114 Mothers against decapentaplegic homolog 6 Proteins 0.000 description 1
102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
108091008877 NK cell receptors Proteins 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282579 Pan Species 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241000282520 Papio Species 0.000 description 1
241000700639 Parapoxvirus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
241001315609 Pittosporum crassifolium Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
101710182846 Polyhedrin Proteins 0.000 description 1
241000282405 Pongo abelii Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
241001415846 Procellariidae Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
102100021782 SH3 domain-containing protein 19 Human genes 0.000 description 1
CDKIEBFIMCSCBB-CALJPSDSSA-N SIS3 Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)\C=C\C(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-CALJPSDSSA-N 0.000 description 1
101700026522 SMAD7 Proteins 0.000 description 1
101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
241000235088 Saccharomyces sp. Species 0.000 description 1
241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
108050007496 Shikimate kinase 2 Proteins 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000003800 Staudinger reaction Methods 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
101710084188 TGF-beta receptor type-2 Proteins 0.000 description 1
201000000331 Testicular germ cell cancer Diseases 0.000 description 1
101710167005 Thiol:disulfide interchange protein DsbD Proteins 0.000 description 1
102000012607 Thrombomodulin Human genes 0.000 description 1
108010079274 Thrombomodulin Proteins 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
102100023132 Transcription factor Jun Human genes 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
102000007238 Transferrin Receptors Human genes 0.000 description 1
102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 description 1
108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
102000044159 Ubiquitin Human genes 0.000 description 1
208000006593 Urologic Neoplasms Diseases 0.000 description 1
201000005969 Uveal melanoma Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
208000014070 Vestibular schwannoma Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
208000017733 acquired polycythemia vera Diseases 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
238000012382 advanced drug delivery Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229910001508 alkali metal halide Inorganic materials 0.000 description 1
150000008045 alkali metal halides Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
102000025171 antigen binding proteins Human genes 0.000 description 1
108091000831 antigen binding proteins Proteins 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000005975 antitumor immune response Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
238000002819 bacterial display Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
235000011175 beta-cyclodextrine Nutrition 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000008512 biological response Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
WBCHEYYIPIQTKY-UHFFFAOYSA-N bis(2h-benzotriazol-4-yl) carbonate Chemical compound C=1C=CC=2NN=NC=2C=1OC(=O)OC1=CC=CC2=C1N=NN2 WBCHEYYIPIQTKY-UHFFFAOYSA-N 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000012930 cell culture fluid Substances 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
210000004520 cell wall skeleton Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000024207 chronic leukemia Diseases 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
201000002660 colon sarcoma Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
201000010918 connective tissue cancer Diseases 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
208000002445 cystadenocarcinoma Diseases 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
238000013499 data model Methods 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
208000024558 digestive system cancer Diseases 0.000 description 1
208000018554 digestive system carcinoma Diseases 0.000 description 1
230000000447 dimerizing effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
GCSAXWHQFYOIFE-UHFFFAOYSA-N dipyridin-2-yl carbonate Chemical compound C=1C=CC=NC=1OC(=O)OC1=CC=CC=N1 GCSAXWHQFYOIFE-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
208000037828 epithelial carcinoma Diseases 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
201000005619 esophageal carcinoma Diseases 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229940093476 ethylene glycol Drugs 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
208000024519 eye neoplasm Diseases 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
201000010231 gastrointestinal system cancer Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
230000009368 gene silencing by RNA Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000003128 head Anatomy 0.000 description 1
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
208000025750 heavy chain disease Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
102000043321 human CTLA4 Human genes 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229960002163 hydrogen peroxide Drugs 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000003832 immune regulation Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
102000028557 immunoglobulin binding proteins Human genes 0.000 description 1
108091009323 immunoglobulin binding proteins Proteins 0.000 description 1
230000003259 immunoinhibitory effect Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940041682 inhalant solution Drugs 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000007689 inspection Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
208000020082 intraepithelial neoplasia Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
229960005386 ipilimumab Drugs 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
238000012332 laboratory investigation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
208000012804 lymphangiosarcoma Diseases 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
229920001427 mPEG Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
208000021937 marginal zone lymphoma Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
238000010208 microarray analysis Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000002991 molded plastic Substances 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
210000001167 myeloblast Anatomy 0.000 description 1
210000003887 myelocyte Anatomy 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
208000001611 myxosarcoma Diseases 0.000 description 1
201000011216 nasopharynx carcinoma Diseases 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
208000025189 neoplasm of testis Diseases 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
201000008106 ocular cancer Diseases 0.000 description 1
230000003606 oligomerizing effect Effects 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000033064 perforin production Effects 0.000 description 1
238000005220 pharmaceutical analysis Methods 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
208000037244 polycythemia vera Diseases 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
238000011176 pooling Methods 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
210000004765 promyelocyte Anatomy 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
238000003498 protein array Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000037425 regulation of transcription Effects 0.000 description 1
230000009712 regulation of translation Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
102000003702 retinoic acid receptors Human genes 0.000 description 1
108090000064 retinoic acid receptors Proteins 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
238000002702 ribosome display Methods 0.000 description 1
238000007151 ring opening polymerisation reaction Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
201000007321 sebaceous carcinoma Diseases 0.000 description 1
239000006152 selective media Substances 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
239000002924 silencing RNA Substances 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000002314 small intestine cancer Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
201000010965 sweat gland carcinoma Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
206010042863 synovial sarcoma Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000011191 terminal modification Methods 0.000 description 1
230000002381 testicular Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
MYVIATVLJGTBFV-UHFFFAOYSA-M thiamine(1+) chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N MYVIATVLJGTBFV-UHFFFAOYSA-M 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
208000008732 thymoma Diseases 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
102000004217 thyroid hormone receptors Human genes 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
229920001664 tyloxapol Polymers 0.000 description 1
229960004224 tyloxapol Drugs 0.000 description 1
230000005951 type IV hypersensitivity Effects 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
229940055760 yervoy Drugs 0.000 description 1